Anixa Biosciences Inc

SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board. "Dr. Guerra has been influential in equitable access to cancer screening and clinical trials, and we are excited to have her join our Cancer Business Advisory Board. We look forward to her input and guidance as we advance our breast cancer vaccine to a Phase 2 clinical trial and continue progressing our ongoing ovarian cancer CAR-T therapy Phase 1 trial," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. Dr. Guerra is the Ruth C. and Raymond G. Perelman Professor of Medicine and Professor of Biostatistics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She is also the Associate Director of Community Outreach and Engagement for the Abramson Cancer Center.  Dr. Guerra's research is focused on developing and evaluating interventions to increase the participation of populations in cancer screening and cancer clinical trials. Dr. Guerra developed and currently oversees the Penn Medicine Colorectal Cancer Screening Navigation Program and the Breast and Cervical Cancer Early Detection Program which have screened thousands of individuals and provided patient navigation to diagnosis and treatment. Dr. Guerra is also the site Principal Investigator of the NCI-funded Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial, a platform trial which compares the accuracy of self- and clinician-collected samples of multiple HPV collection kits and assays. The results of the SHIP trial are being submitted to the FDA and led to the approval of the first at home HPV test for cervical cancer screening. Dr. Guerra also is member of the American Cancer Society (ACS) Clinical Guidelines Development group and an author of the ACS colorectal, cervical, lung, and prostate clinical practice guidelines and the ACS guidance to clinicians for Multi-cancer Early Detection Tests, all which widely influence clinical practice.  Dr. Guerra was a member of the national board of directors of the American Cancer Society from 2016 to 2023 and served as the Board Scientific Officer. "I am honored to join Anixa Bioscience's advisory board as the company advances promising clinical trials in breast cancer and ovarian cancer, two areas with significant unmet needs. I am looking forward to contributing to the board's efforts and collaborating with this distinguished group of advisors assembled by Anixa, which includes many colleagues that I have been privileged to work with throughout my career," Dr. Guerra stated.  About Anixa Biosciences' Cancer Business Advisory BoardAnixa's Cancer Business Advisory Board is an elite group that includes members such as Karen Knudsen, Ph.D., and Gary Reedy, both previous CEOs of the American Cancer Society, and Mike Shepard, Ph.D., inventor of Herceptin, among many others. The full membership and corresponding biographies can be found on the Anixa website.

SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million homes across the U.S. During the interview, Dr. Kumar will discuss recently announced successes in cancer vaccine development and Anixa's breast cancer vaccine that is expected to be used not only to treat cancer and to prevent recurrence, but also as a preventive vaccine to reduce the risk of ever developing breast cancer. In addition, Sherie Steinberg, a breast cancer survivor who participated in Anixa's Phase 1 clinical trial, will discuss her breast cancer journey and her experience receiving Anixa's vaccine. You may view the segment on Bloomberg TV (for channel information, check your local listings) or on the internet at https://www.youtube.com/watch?v=jCUvJY2bjNU. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com&nbsp

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters. Anixa's presentation will be held at 3:40 PM PT with a breakout session to follow. Dr. Kumar's presentation will provide updates on both of Anixa's clinical programs, a CAR-T therapy for recurrent and resistant ovarian cancer, which is being evaluated in an ongoing Phase 1 trial in collaboration with Moffitt Cancer Center that is producing encouraging survival data and no dose-limited toxicities observed to date, and the recently completed Phase 1 trial of its therapeutic and prophylactic breast cancer vaccine conducted at Cleveland Clinic and funded by the U.S. Department of Defense, that met all primary endpoints. Dr. Kumar will also discuss future plans for the Phase 2 trial of the vaccine. "We are pleased to be invited to this inaugural event to discuss our company. My presentation will primarily focus on our breast cancer vaccine, especially in light of the recent news about the success in a Phase 3 trial of a personalized vaccine in melanoma. We are encouraged by this success, and we feel that our Phase 1 vaccine trial produced similarly positive results as the earlier melanoma vaccine's Phase 1 trial, even though the two programs are testing different approaches," stated Dr. Kumar. Presentation details: Event:  Nasdaq & LD Micro Inaugural SF Summit Date:  September 9, 2026Time:  3:40 PM PT Location:  Nasdaq Headquarters, 350 Mission St., 11th Floor, San Francisco, California The Nasdaq & LD Micro Inaugural SF Summit brings together a select group of public companies, each delivering a presentation to institutional investors. Each presenting company will also participate in breakout sessions immediately following their presentations, allowing interested investors to ask questions and engage directly with management. Investors interested in meeting with Anixa should contact their LD Micro representative. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in colla

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York City. Mike Catelani, President, COO & CFO of Anixa, will deliver a presentation highlighting Anixa's breast cancer vaccine, being developed in collaboration with Cleveland Clinic, which completed a Phase 1 clinical trial that was funded by the U.S. Department of Defense. The trial met all primary endpoints, including safety, and protocol-defined immune responses were generated in 74% of participants. Preparations are underway for a Phase 2 trial.  "The recent presentation of preliminary data by Merck and Moderna for their personalized melanoma vaccine reinforces the growing potential of cancer vaccines as an important new approach to both treating and preventing cancer. Anixa is already advancing within this field with a vaccine designed to both treat and prevent breast cancer. Following the encouraging results from our Phase 1 trial, we are now preparing to advance the program into Phase 2 studies," stated Dr. Amit Kumar, Chairman and CEO of Anixa. Mr. Catelani will also discuss Anixa's ovarian cancer CAR-T therapy, liraltagene-autoleucel, or lira-cel, which is being evaluated in an ongoing Phase 1 clinical trial in collaboration with Moffitt Cancer Center. Participants in this trial are highly pre-treated, recurrent and resistant ovarian cancer patients, who have failed conventional therapies and are progressing. In the lira-cel trial, dosing has advanced to the fifth and highest cohort evaluated to date, which incorporates lymphodepletion for the first time. No dose-limiting toxicities have been observed in the study to date, and four patients have surpassed one year of survival following treatment, with the longest at approximately 28 months. "This is an exciting time for Anixa, with our breast cancer vaccine advancing toward Phase 2 and our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial," said Mr. Catelani, "We look forward to sharing our progress in future." Presentation details: Event:  2026 Cantor Fitzgerald Global Healthcare ConferenceDate:  September 11, 2026Time:  8:00 AM ET Location:  Waldorf Astoria New York (301 Park Avenue) Management will be available for one-on-one meetings during the conference. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14 – 16, 2026. Dr. Amit Kumar, Chairman and CEO of Anixa, will deliver a presentation that will be available to view beginning at 7:00 AM ET, Friday, September 11, 2026. Dr. Kumar's presentation will highlight Anixa's breast cancer vaccine, being developed in collaboration with Cleveland Clinic, which completed a Phase 1 clinical trial that was funded by the U.S. Department of Defense. The trial met all primary endpoints, including safety, and protocol-defined immune responses were generated in 74% of participants. Preparations are underway for a Phase 2 trial.  Dr. Kumar will also discuss Anixa's ovarian cancer CAR-T therapy, liraltagene-autoleucel, or lira-cel, which is being evaluated in an ongoing Phase 1 clinical trial in collaboration with Moffitt Cancer Center. Participants in this trial are highly pre-treated, recurrent and resistant ovarian cancer patients, who have failed conventional therapies and are progressing. In the lira-cel trial, dosing has advanced to the fifth and highest cohort evaluated to date, which incorporates lymphodepletion for the first time. No dose-limiting toxicities have been observed in the study to date, and four patients have surpassed one year of survival following treatment, with the longest at approximately 28 months. "This is an exciting time for Anixa, with our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial and our breast cancer vaccine advancing toward Phase 2," said Dr. Kumar. "We look forward to sharing our progress in the coming weeks." Details to view the presentation are as follows: Event:  H.C. Wainwright 28th Annual Global Investment ConferenceDate & time:  Beginning at 7:00 AM ET, September 11, 2026, and will remain available for 90 days Webcast:  https://journey.ct.events/view/95700413-04bd-4a6f-b873-84a7fe7aeb5e Management will be available for one-on-one meetings during the conference. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeuti